Francis Crick Institute Bonus Episode: Cancer biology, vaccines, NK cells and immunotherapy explained

Episode overview

This bonus episode from A Question of Science brings together Charlie Swanton and Gerard Evan from the Francis Crick Institute to explore the science of cancer, including how cancers kill, advances in prevention and treatment, and the complex biology that shapes patient outcomes. The discussion traverses autopsy studies of cancer patients, vaccine strategies to prevent cancer initiation, the activity of natural killer cells, and the metabolic vulnerabilities of tumours, with reflections on patient wellbeing and public understanding of cancer biology.

• Key insight: cancer deaths arise from multiple organ dysfunction and systemic effects rather than a single cause.
• Key insight: vaccines targeting early cancer mutations may prevent cancer initiation in high risk individuals.
• Key insight: innate immune cells, especially natural killer cells, play a crucial role in surveilling and attacking tumours.
• Key insight: cancer metabolism and key oncogenes like MYC influence progression and therapeutic strategies.

Overview

The Crick Institute bonus episode delves into the science of cancer with two leading researchers, focusing on how cancers kill, how prevention and treatment are evolving, and how the body’s immune system interacts with tumours. The conversation emphasizes that cancer is not a single disease but a collection of pathologies that can disrupt organ function, coagulation, and systemic physiology. A central theme is the balance between controlling cancer and managing the patient’s overall health and quality of life.

Key topics and insights

Discussion centers on the diverse mechanisms by which cancer causes morbidity and mortality, including metastasis, liver dysfunction, hypercoagulation, and tumour mass effects. The speakers describe an autopsy program funded by Cancer Research UK to understand how patients die from cancer, revealing that disease burden does not always correlate with longevity and that systemic effects can dominate outcomes. The team also explores how cancer can impair immune responses to infections, highlighting the immune system’s complex interplay with cancer.

Cancer prevention and vaccines

A major portion is devoted to vaccines designed to prevent cancer initiation in high-risk individuals. Researchers discuss mapping common early initiating mutations in lung cancer among heavy smokers and developing an mRNA vaccine to target these mutations. The aim is to vaccinate high-risk groups and remanent cancer patients to prevent second primaries by boosting immune recognition of early clones before they become radiographically detectable.

Immunotherapy and innate immunity

The conversation covers both adaptive and innate immune responses. In particular, natural killer (NK) cells are described as surveillance cells that detect stressed tissues and tumours that have downregulated major histocompatibility complex molecules. The discussion also touches on the challenges of cancer evolution and the potential of therapies that exploit NK cell sensing of immune-escape strategies.

Stem cells and cancer therapy

Stem cell transplantation is discussed in the context of blood cancers, with debates about its use in solid tumours. The panel notes the substantial risks of transplantation and the preclinical concerns that stimulating certain immune cell lineages could inadvertently support tumour growth in some settings.

Metabolism, MYC and wound healing

The speakers reflect on the concept that cancers hijack normal developmental and wound healing programs. They highlight the MYC oncogene as a driver of a wound-healing–like gene expression program, suggesting that turning MYC off could suppress tumours in preclinical models. This line of thinking frames cancer less as a disease with a single villain gene and more as a dysregulated version of normal tissue repair pathways.

Psychological factors and pediatric cancer

The discussion also addresses patient wellbeing, including cancer cachexia, depression associated with cancer, and the brain–tumour communication that may influence appetite and mood. The presenters caution against assuming that improving mental health alone will improve survival, noting that controlling the underlying cancer is essential for meaningful improvements in quality of life.